These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 22261445)

  • 1. p53 nuclear expression correlates with hemizygous TP53 deletion and predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with lenalidomide.
    Chen MH; Qi CX; Saha MN; Chang H
    Am J Clin Pathol; 2012 Feb; 137(2):208-12. PubMed ID: 22261445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclin kinase subunit 1B nuclear expression predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with bortezomib.
    Chen MH; Qi C; Reece D; Chang H
    Hum Pathol; 2012 Jun; 43(6):858-64. PubMed ID: 22047644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aberrant nuclear p53 expression predicts hemizygous 17p (TP53) deletion in chronic lymphocytic leukemia.
    Chang H; Jiang AM; Qi CX
    Am J Clin Pathol; 2010 Jan; 133(1):70-4. PubMed ID: 20023260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone.
    Avet-Loiseau H; Soulier J; Fermand JP; Yakoub-Agha I; Attal M; Hulin C; Garderet L; Belhadj K; Dorvaux V; Minvielle S; Moreau P;
    Leukemia; 2010 Mar; 24(3):623-8. PubMed ID: 20072152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aberrant nuclear p53 protein expression detected by immunohistochemistry is associated with hemizygous P53 deletion and poor survival for multiple myeloma.
    Chang H; Yeung J; Qi C; Xu W
    Br J Haematol; 2007 Aug; 138(3):324-9. PubMed ID: 17555471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy.
    Boyd KD; Ross FM; Tapper WJ; Chiecchio L; Dagrada G; Konn ZJ; Gonzalez D; Walker BA; Hockley SL; Wardell CP; Gregory WM; Child JA; Jackson GH; Davies FE; Morgan GJ;
    Genes Chromosomes Cancer; 2011 Oct; 50(10):765-74. PubMed ID: 21961181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies.
    Dimopoulos MA; Kastritis E; Christoulas D; Migkou M; Gavriatopoulou M; Gkotzamanidou M; Iakovaki M; Matsouka C; Mparmparoussi D; Roussou M; Efstathiou E; Terpos E
    Leukemia; 2010 Oct; 24(10):1769-78. PubMed ID: 20739955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of cyclin D1, fibroblast growth factor receptor 3, and p53 immunohistochemistry in plasma cell myeloma treated with a thalidomide-based regimen.
    Kelley TW; Baz R; Hussein M; Karafa M; Cook JR
    Hum Pathol; 2009 Mar; 40(3):405-12. PubMed ID: 19070887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13.
    Reece D; Song KW; Fu T; Roland B; Chang H; Horsman DE; Mansoor A; Chen C; Masih-Khan E; Trieu Y; Bruyere H; Stewart DA; Bahlis NJ
    Blood; 2009 Jul; 114(3):522-5. PubMed ID: 19332768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma.
    Dimopoulos MA; Chen C; Spencer A; Niesvizky R; Attal M; Stadtmauer EA; Petrucci MT; Yu Z; Olesnyckyj M; Zeldis JB; Knight RD; Weber DM
    Leukemia; 2009 Nov; 23(11):2147-52. PubMed ID: 19626046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone.
    Klein U; Jauch A; Hielscher T; Hillengass J; Raab MS; Seckinger A; Hose D; Ho AD; Goldschmidt H; Neben K
    Cancer; 2011 May; 117(10):2136-44. PubMed ID: 21523726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
    Dimopoulos M; Spencer A; Attal M; Prince HM; Harousseau JL; Dmoszynska A; San Miguel J; Hellmann A; Facon T; Foà R; Corso A; Masliak Z; Olesnyckyj M; Yu Z; Patin J; Zeldis JB; Knight RD;
    N Engl J Med; 2007 Nov; 357(21):2123-32. PubMed ID: 18032762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.
    Richardson P
    Semin Hematol; 2005 Oct; 42(4 Suppl 4):S9-15. PubMed ID: 16344100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 1p21 deletions are strongly associated with 1q21 gains and are an independent adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma.
    Chang H; Qi X; Jiang A; Xu W; Young T; Reece D
    Bone Marrow Transplant; 2010 Jan; 45(1):117-21. PubMed ID: 19448682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients.
    Grzasko N; Hus M; Pluta A; Jurczyszyn A; Walter-Croneck A; Morawska M; Chocholska S; Hajek R; Dmoszynska A
    Hematol Oncol; 2013 Mar; 31(1):41-8. PubMed ID: 22674819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone.
    Chang H; Jiang A; Qi C; Trieu Y; Chen C; Reece D
    Leuk Lymphoma; 2010 Nov; 51(11):2084-91. PubMed ID: 20929319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment.
    Klein U; Neben K; Hielscher T; Heiss C; Ho AD; Goldschmidt H
    Ann Hematol; 2011 Apr; 90(4):429-39. PubMed ID: 20857112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of TP53 mutations with the AmpliChip p53 research test in chronic lymphocytic leukemia: correlation with clinical outcome and gene expression profiling.
    Chiaretti S; Tavolaro S; Marinelli M; Messina M; Del Giudice I; Mauro FR; Santangelo S; Piciocchi A; Peragine N; Truong S; Patten N; Ghia EM; Torrente I; De Propris MS; Nanni M; Lawrence J; Guarini A; Foà R
    Genes Chromosomes Cancer; 2011 Apr; 50(4):263-74. PubMed ID: 21319261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lenalidomide: new drug. Myeloma: many questions remain unanswered.
    Prescrire Int; 2008 Dec; 17(98):230-2. PubMed ID: 19422142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion.
    Sagaster V; Ludwig H; Kaufmann H; Odelga V; Zojer N; Ackermann J; Küenburg E; Wieser R; Zielinski C; Drach J
    Leukemia; 2007 Jan; 21(1):164-8. PubMed ID: 17096015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.